Nebilan (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic blocker used primarily in the management of hypertension and related cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack.
• Heart failure with reduced ejection fraction: improves cardiac output and may decrease hospitalization rates.
• Cardiovascular risk reduction in hypertensive patients: helps prevent major adverse cardiovascular events when combined with standard therapy.

• Nebivolol acts as a highly selective β1‑adrenergic receptor antagonist, reducing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide release and vasodilation, which together contribute to a sustained decrease in systemic vascular resistance and blood pressure.

Nebivolol may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Dizziness or light‑headedness: especially after standing.
• Fatigue: feeling of tiredness or reduced energy.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Bradycardia: abnormally slow heart rate that may require medical attention.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Acute bronchospasm: sudden narrowing of airways, particularly in patients with asthma.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure patient safety.

• Cardiovascular assessment: evaluate heart rate and blood pressure before initiation.
• Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchoconstriction.
• Diabetes mellitus: monitor blood glucose as β‑blockade may mask hypoglycaemia symptoms.
• Liver impairment: dose adjustment may be required in moderate to severe hepatic dysfunction.
• Concomitant AV nodal blockers: avoid excessive bradycardia when combined with other rate‑controlling agents.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined use with non‑selective β‑blockers: may cause excessive β‑blockade and bradycardia.
• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels, raising risk of adverse effects.
• Calcium channel blockers (verapamil, diltiazem): can enhance negative inotropic and chronotropic effects.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents (ACE inhibitors, diuretics): may produce additive blood pressure lowering.
• Antidiabetic drugs (insulin, sulfonylureas): β‑blockade may mask hypoglycaemia signs.
• Antidepressants (tricyclics): may increase risk of cardiac conduction abnormalities.